The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on 23rd May, 2025, which commenced at 02.00 p.m. and concluded at 04:54 p.m., considered and approved the following: 1. Audited Financial Results for the quarter and year ended March 31, 2025. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com. 2. Recommended Dividend @ 250% i.e. Rs. 2.5/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2024-25 subject to the approval of the Shareholders at the ensuing Annual General Meeting.